Octreotide

growth hormone 1 ; Homo sapiens







192 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34741720 Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers. 2022 Feb 2
2 35199646 Acromegaly caused by a GHRH-producing pancreatic neuroendocrine tumor: a rare manifestation of MEN1 syndrome. 2022 Feb 1 1
3 34599040 Novel Platform for Predicting Drug Effects in Patients with Acromegaly: Translational Exposure-Response Evaluation of Growth Hormone-Inhibitory Effect of Octreotide after Growth Hormone-Releasing Hormone Stimulation. 2021 Dec 5
4 32859050 Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. 2020 Aug 26 1
5 29699852 Relative Bioavailability of a Single 4-mg Dose of Somatropin Administered by Subcutaneous Injection or by Needle-free Device and Coadministered With the Growth Hormone Inhibitor Octreotide Acetate in Healthy Adult Subjects. 2018 May 1
6 28260048 Octreotide inhibits the proliferation of gastric cancer cells through P300-HAT activity and the interaction of ZAC and P300. 2017 Apr 2
7 26610414 New therapeutic agents for acromegaly. 2016 Feb 1
8 26951062 Somatostatin and its Analogs. 2016 1
9 27376425 Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center. 2016 Apr 1
10 27657985 Comparative pharmacokinetic and pharmacodynamic evaluation between a new biosimilar and reference recombinant human growth hormone. 2016 Oct - Dec 1
11 25345412 Evaluation of the antiangiogenic effects of octreotide on growth hormone-producing pituitary adenoma using arterial spin-labeling perfusion imaging. 2015 2
12 26115707 Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: a meta-analysis. 2015 Dec 2
13 26361517 Glycemic profile in patients with acromegaly treated with somatostatin analogue. 2015 1
14 24166706 The role of primary pharmacological therapy in acromegaly. 2014 Jan 1
15 25132171 Thyroid storm induced by TSH-secreting pituitary adenoma: a case report. 2014 1
16 25253414 Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly. 2014 Oct 1
17 22539587 Oral octreotide absorption in human subjects: comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. 2012 Jul 1
18 22574156 Meta-analysis on the effects of octreotide on tumor mass in acromegaly. 2012 2
19 22784835 A subcutaneous octreotide hydrogel implant for the treatment of acromegaly. 2012 Nov-Dec 1
20 22990736 Ectopic growth hormone-secreting pituitary adenoma involving the clivus treated with octreotide: role of magnetic resonance imaging in the diagnosis and clinical follow-up. 2012 Sep 1
21 23148190 The efficacy of octreotide LAR in acromegalic patients as primary or secondary therapy. 2012 Feb 2
22 21521254 Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure. 2011 Jun 3
23 21979989 Octreotide for the treatment of systemic lupus erythematosus: clinical effects and an in vitro study on its therapeutic mechanism. 2011 Oct 2
24 19884028 Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR. 2010 Apr 1
25 20067380 Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge. 2010 Jan 1
26 20464704 Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5? 2010 Mar-Apr 5
27 20723227 Symptomatic cerebral oedema during treatment of diabetic ketoacidosis: effect of adjuvant octreotide infusion. 2010 Aug 19 2
28 22791498 Normalisation of plasma growth hormone levels improved cardiac dysfunction due to acromegalic cardiomyopathy with severe fibrosis. 2010 Sep 19 2
29 19164866 Analyses of factors influencing the acute effect of octreotide in growth hormone-secreting adenomas. 2009 6
30 19420816 Improvement of congestive heart failure after octreotide and transsphenoidal surgery in a patient with acromegaly. 2009 1
31 19625744 Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. 2009 1
32 19697885 [Recent trends in the pathophysiology and treatment of pituitary adenomas]. 2009 Aug 1
33 18198230 Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. 2008 Apr 1
34 18230656 Low levels of raf kinase inhibitory protein in growth hormone-secreting pituitary adenomas correlate with poor response to octreotide treatment. 2008 Apr 1
35 18348909 Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. 2008 Oct 1
36 18445999 Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. 2008 Jul 2
37 18593770 Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. 2008 Sep 1
38 19074883 Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. 2008 Dec 15 5
39 17289896 Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. 2007 Feb 1 3
40 17309144 Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly. 2007 Feb 1
41 17642426 Successful treatment of an invasive growth hormone-secreting pituitary macroadenoma in an 8-year-old boy. 2007 May 2
42 20298292 Yellow nail syndrome: treatment with octreotide. 2007 Dec 1
43 16269873 Pegvisomant treatment in a 4-year-old girl with neurofibromatosis type 1. 2006 1
44 16584524 Inadequate growth hormone suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' growth hormone levels. 2006 Apr 2
45 16817834 Inadequate growth hormone (GH) suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' GH levels. 2006 Jul 3
46 16840917 An unusual somatotropin and thyreotropin secreting pituitary adenoma efficiently controlled by Octreotide and Pegvisomant. 2006 Jun 2
47 17047391 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. 2006 2
48 31627642 [Drug treatment for acromegaly: results of long-term use of Sandostatin LAR]. 2006 Aug 15 4
49 15806331 Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study. 2005 May 1
50 15844307 Effect of preoperative use of long-acting octreotide on growth hormone secreting pituitary adenoma and transsphenoidal surgery. 2005 Mar 2